Sartorius - Public Comps and Valuation Multiples

Sartorius Overview

About Sartorius

Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.

Founded

1870

HQ

Employees

13.5K+

Website

sartorius.com

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue $3.7B

LTM EBITDA $1.0B

EV

$16.5B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Sartorius Financials

Sartorius has a last 12-month revenue of $3.7B and a last 12-month EBITDA of $1.0B.

In the most recent fiscal year, Sartorius achieved revenue of $3.6B and an EBITDA of $845M.

Sartorius expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Sartorius valuation multiples based on analyst estimates

Sartorius P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$3.6B	$3.6B	XXX	XXX	XXX
Gross Profit	$2.4B	$1.7B	XXX	XXX	XXX
Gross Margin	65%	46%	XXX	XXX	XXX
EBITDA	$938M	$845M	XXX	XXX	XXX
EBITDA Margin	26%	23%	XXX	XXX	XXX
Net Profit	$728M	$220M	XXX	XXX	XXX
Net Margin	20%	6%	XXX	XXX	XXX
Net Debt	$2.4B	$5.1B	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Sartorius Stock Performance

As of April 15, 2025, Sartorius's stock price is EUR 168 (or $180).

Sartorius has current market cap of EUR 11.6B (or $12.4B), and EV of EUR 15.3B (or $16.5B).

See Sartorius trading valuation data

Sartorius Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$16.5B	$12.4B	XXX	XXX	XXX	XXX	$4.61

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sartorius Valuation Multiples

As of April 15, 2025, Sartorius has market cap of $12.4B and EV of $16.5B.

Sartorius's trades at 4.4x LTM EV/Revenue multiple, and 15.7x LTM EBITDA.

Analysts estimate Sartorius's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Sartorius and 10K+ public comps

Sartorius Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$16.5B	XXX	XXX	XXX
EV/Revenue	4.5x	XXX	XXX	XXX
EV/EBITDA	19.5x	XXX	XXX	XXX
P/E	138.0x	XXX	XXX	XXX
P/E/Growth	1.2x	XXX	XXX	XXX
EV/FCF	27.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sartorius Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sartorius Valuation Multiples

Sartorius's NTM/LTM revenue growth is 8%

Sartorius's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Sartorius's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Sartorius's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Sartorius and other 10K+ public comps

Sartorius Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	0%	XXX	XXX	XXX	XXX
EBITDA Margin	23%	XXX	XXX	XXX	XXX
EBITDA Growth	-10%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	31%	XXX	XXX	XXX	XXX
Revenue per Employee	$0.3M	XXX	XXX	XXX	XXX
Opex per Employee	$0.1M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	20%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	6%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	6%	XXX	XXX	XXX	XXX
Opex to Revenue	32%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry